메뉴 건너뛰기




Volumn 1, Issue 6, 2015, Pages 737-745

Impact of chemotherapy dosing on ovarian cancer survival according to body mass index

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL;

EID: 85010903606     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1796     Document Type: Article
Times cited : (40)

References (31)
  • 1
    • 84969908932 scopus 로고    scopus 로고
    • Atlanta, GA: American Cancer Society
    • American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society; 2015.
    • (2015) Cancer Facts and Figures 2015
  • 2
    • 84855999990 scopus 로고    scopus 로고
    • Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer
    • Nagel CI, Backes FJ, Hade EM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012;124(2):221-224.
    • (2012) Gynecol Oncol. , vol.124 , Issue.2 , pp. 221-224
    • Nagel, C.I.1    Backes, F.J.2    Hade, E.M.3
  • 3
    • 79959774261 scopus 로고    scopus 로고
    • Recent progress in the diagnosis and treatment of ovarian cancer
    • Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
    • (2011) CA Cancer J Clin. , vol.61 , Issue.3 , pp. 183-203
    • Jelovac, D.1    Armstrong, D.K.2
  • 4
    • 46749096115 scopus 로고    scopus 로고
    • Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey
    • Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract. 2008;4(3):108-113.
    • (2008) J Oncol Pract. , vol.4 , Issue.3 , pp. 108-113
    • Field, K.M.1    Kosmider, S.2    Jefford, M.3
  • 5
    • 84862986506 scopus 로고    scopus 로고
    • Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline
    • Griggs JJ, Mangu PB, Anderson H, et al; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13): 1553-1561.
    • (2012) J Clin Oncol. , vol.30 , Issue.13 , pp. 1553-1561
    • Griggs, J.J.1    Mangu, P.B.2    Anderson, H.3
  • 7
    • 25444485782 scopus 로고    scopus 로고
    • The impact of obesity on the incidence and treatment of gynecologic cancers: A review
    • Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv. 2005;60(10):683-692.
    • (2005) Obstet Gynecol Surv. , vol.60 , Issue.10 , pp. 683-692
    • Modesitt, S.C.1    Van Nagell, J.R.2
  • 8
    • 67349205883 scopus 로고    scopus 로고
    • Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    • Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115-122.
    • (2009) Cancer Chemother Pharmacol. , vol.64 , Issue.1 , pp. 115-122
    • Ekhart, C.1    Rodenhuis, S.2    Schellens, J.H.3    Beijnen, J.H.4    Huitema, A.D.5
  • 9
    • 85006302488 scopus 로고    scopus 로고
    • Carboplatin dosing in overweight and obese patients: A single-center experience
    • Nightingale G, Trovato JA, Lee M, Thompson J. Carboplatin dosing in overweight and obese patients: a single-center experience. J Hematol Oncol Pharm. 2011;1:18-24.
    • (2011) J Hematol Oncol Pharm. , vol.1 , pp. 18-24
    • Nightingale, G.1    Trovato, J.A.2    Lee, M.3    Thompson, J.4
  • 10
    • 84937522221 scopus 로고    scopus 로고
    • The HMO Research Network Virtual Data Warehouse: A public data model to support collaboration
    • Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC). 2014;2(1):1049.
    • (2014) EGEMS (Wash DC). , vol.2 , Issue.1 , pp. 1049
    • Ross, T.R.1    Ng, D.2    Brown, J.S.3
  • 12
    • 0025663391 scopus 로고
    • The calculation of received dose intensity
    • Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12): 1935-1937.
    • (1990) J Clin Oncol. , vol.8 , Issue.12 , pp. 1935-1937
    • Hryniuk, W.M.1    Goodyear, M.2
  • 14
    • 33846933756 scopus 로고    scopus 로고
    • Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
    • Griggs JJ, Culakova E, Sorbero ME, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007;25(3):277-284.
    • (2007) J Clin Oncol. , vol.25 , Issue.3 , pp. 277-284
    • Griggs, J.J.1    Culakova, E.2    Sorbero, M.E.3
  • 15
    • 84875451592 scopus 로고    scopus 로고
    • Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer
    • Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74-80.
    • (2013) Gynecol Oncol. , vol.129 , Issue.1 , pp. 74-80
    • Hanna, R.K.1    Poniewierski, M.S.2    Laskey, R.A.3
  • 16
    • 84897082114 scopus 로고    scopus 로고
    • Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)
    • Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014; 133(1):16-22.
    • (2014) Gynecol Oncol. , vol.133 , Issue.1 , pp. 16-22
    • Au-Yeung, G.1    Webb, P.M.2    DeFazio, A.3    Fereday, S.4    Bressel, M.5    Mileshkin, L.6
  • 17
    • 80051548582 scopus 로고    scopus 로고
    • Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer
    • Fauci JM, Whitworth JM, Schneider KE, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol. 2011;122 (3):532-535.
    • (2011) Gynecol Oncol. , vol.122 , Issue.3 , pp. 532-535
    • Fauci, J.M.1    Whitworth, J.M.2    Schneider, K.E.3
  • 18
    • 65549105066 scopus 로고    scopus 로고
    • Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology studies S8814/S8897
    • Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27(13): 2157-2162.
    • (2009) J Clin Oncol. , vol.27 , Issue.13 , pp. 2157-2162
    • Hershman, D.L.1    Unger, J.M.2    Barlow, W.E.3
  • 19
    • 84899638961 scopus 로고    scopus 로고
    • The influence of comorbidity on mortality in ovarian cancer patients
    • Stålberg K, Svensson T, Lönn S, Kieler H. The influence of comorbidity on mortality in ovarian cancer patients. Gynecol Oncol. 2014;133(2):298-303.
    • (2014) Gynecol Oncol. , vol.133 , Issue.2 , pp. 298-303
    • Stålberg, K.1    Svensson, T.2    Lönn, S.3    Kieler, H.4
  • 20
    • 84876290864 scopus 로고    scopus 로고
    • Prevalence and incidence of comorbidities in elderly women with ovarian cancer
    • Chia VM, O'Malley CD, Danese MD, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346-352.
    • (2013) Gynecol Oncol. , vol.129 , Issue.2 , pp. 346-352
    • Chia, V.M.1    O'Malley, C.D.2    Danese, M.D.3
  • 21
    • 84859625302 scopus 로고    scopus 로고
    • Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy
    • Rodriguez N, Rauh-Hain JA, Shoni M, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362-366.
    • (2012) Gynecol Oncol. , vol.125 , Issue.2 , pp. 362-366
    • Rodriguez, N.1    Rauh-Hain, J.A.2    Shoni, M.3
  • 22
    • 84920733816 scopus 로고    scopus 로고
    • CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy
    • Pelissier A, Bonneau C, Chéreau E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135(3):542-546.
    • (2014) Gynecol Oncol. , vol.135 , Issue.3 , pp. 542-546
    • Pelissier, A.1    Bonneau, C.2    Chéreau, E.3
  • 23
    • 43049127201 scopus 로고    scopus 로고
    • Does body mass index affect progression-free or overall survival in patients with ovarian cancer results from SCOTROC i trial
    • Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM; Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? results from SCOTROC I trial. Ann Oncol. 2008;19(5):898-902.
    • (2008) Ann Oncol. , vol.19 , Issue.5 , pp. 898-902
    • Barrett, S.V.1    Paul, J.2    Hay, A.3    Vasey, P.A.4    Kaye, S.B.5    Glasspool, R.M.6
  • 24
    • 44549088304 scopus 로고    scopus 로고
    • Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
    • Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109(3):353-358.
    • (2008) Gynecol Oncol. , vol.109 , Issue.3 , pp. 353-358
    • Wright, J.D.1    Tian, C.2    Mutch, D.G.3
  • 26
    • 84881479689 scopus 로고    scopus 로고
    • Chemotherapy dosing in overweight and obese patients with cancer
    • Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013;10(8):451-459.
    • (2013) Nat Rev Clin Oncol. , vol.10 , Issue.8 , pp. 451-459
    • Lyman, G.H.1    Sparreboom, A.2
  • 27
    • 0027281461 scopus 로고
    • The impact of received dose intensity on the outcome of advanced ovarian cancer
    • Repetto L, Pace M, Mammoliti S, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer. 1993;29A(2):181-184.
    • (1993) Eur J Cancer. , vol.29 A , Issue.2 , pp. 181-184
    • Repetto, L.1    Pace, M.2    Mammoliti, S.3
  • 28
    • 84880075063 scopus 로고    scopus 로고
    • Functional range of creatinine clearance for renal drug dosing: A practical solution to the controversy of which weight to use in the Cockcroft-Gault equation
    • Brown DL, Masselink AJ, Lalla CD. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother. 2013;47(7-8):1039-1044.
    • (2013) Ann Pharmacother. , vol.47 , Issue.7-8 , pp. 1039-1044
    • Brown, D.L.1    Masselink, A.J.2    Lalla, C.D.3
  • 29
    • 84856487711 scopus 로고    scopus 로고
    • Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010
    • Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497.
    • (2012) JAMA. , vol.307 , Issue.5 , pp. 491-497
    • Flegal, K.M.1    Carroll, M.D.2    Kit, B.K.3    Ogden, C.L.4
  • 30
    • 0037629061 scopus 로고    scopus 로고
    • Stage at diagnosis of ovarian cancer in the United States, 1992-1997
    • Goodman MT, Correa CN, Tung KH, et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 2003;97(10)(suppl):2648-2659.
    • (2003) Cancer. , vol.97 , Issue.10 , pp. 2648-2659
    • Goodman, M.T.1    Correa, C.N.2    Tung, K.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.